The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new national,...
Read More
PhRMA CEO Statement Following Meeting With President Trump

This morning, we had a positive, productive meeting with President Trump, Vice President Pence and House Energy and Commerce Chairman Greg Walden, (R-Ore.). We talked about how we can work together...
Read More
Medicare Monday: How Part D helps patients with heart disease live longer, healthier lives

Wednesday kicks off American Heart Month, so this week we’re looking at heart health and how important it is for patients to have access to needed medicines for heart disease and stroke. This is...
Read More
Ask About Adherence: Q&A on appointment-based medication synchronization

Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we spoke with David A. Holdford, Ph.D., Professor, Director of International...
Read More
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY

PhRMA President and CEO Stephen J. Ubl spoke with the anchors of CNBC’s Squawk on the Street about the biopharmaceutical industry’s new national, multi-year advertising and public affairs campaign: GO
Read More
Medicare Monday: How Medicare helps beneficiaries access needed medicines

Throughout 2016, we looked at how different groups of beneficiaries – from seniors to minority communities to individuals with lower-incomes – rely on Medicare to access their needed prescription...
Read More
Medicare Monday: A closer look at Medicare Part B

We took a deeper dive on Medicare Part D last week, so today we’re switching gears and talking about Medicare Part B.
Read More
The 20-year journey yielding a new weapon against cancer

Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...
Read More
Significant progress fighting cancer: Death rate has dropped 25 percent

Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, the cancer death rate in...
Read More
Medicare Monday: A refresh on private negotiation in Part D

Last week, we highlighted a number of Medicare resources – from how to learn more about which medicines are covered in Part B to how Part D has been a success since its implementation. And this week,...
Read More
3 things to know about 2016 drug approvals

In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need. These...
Read More
Medicare Monday: Kicking off 2017 with Medicare resources

Happy New Year, #MedicareMonday readers!
Read More